Multicenter review of a tadalafil suspension formulation for infants and children with pulmonary hypertension: A North American experience.
Publication/Presentation Date
1-1-2023
Abstract
INTRODUCTION: Phosphodiesterase type 5 (PDE5) inhibitors, with sildenafil the earliest among them, are widely used in the management of pediatric pulmonary arterial hypertension (PAH). Tadalafil is a PDE5 inhibitor with a long half life (16 h), stable pharmacokinetics and pharmacodynamics, and minimal adverse effects. However, the utility of tadalafil suspensions in this setting has not been widely explored due to a lack of clinical experience. We present a multicenter experience that details the safety and tolerability of a tadalafil suspension, either alone or in combination with another vasodilator, for the management of pediatric pulmonary hypertension (PH).
METHODS AND MATERIALS: This is a retrospective chart review of infants and children at Children's Wisconsin and the Stollery Children's Hospital enrolled in pediatric PH programs between December 2013 and April 2022 managed with a tadalafil suspension. Patients aged six years of age and under who were treated with a tadalafil suspension were included. Demographics, clinical information, echocardiographic and hemodynamic measurements, and laboratory data were collected before and six months after tadalafil initiation.
RESULTS: Over the study period, 154 children with a median age of 1.0 (range 0.0-6.9) years were treated with tadalafil therapy. Of these, 39 (25.3%) were in group 1 (PAH), 79 (51.3%) were in group 3 (lung disease), and 33 (21.4%) were in group 5 (pulmonary hypertensive vascular disease). The median initial dose of tadalafil was 1.0 mg/kg once daily. Eleven (7.1%) patients in the cohort were established on tadalafil therapy
CONCLUSION: Tadalafil, a long-acting PDE5 inhibitor, when administered in a suspension formulation, has a safe and tolerable adverse effect profile. Following six months of therapy, our cohort showed improvements in clinical parameters, echocardiographic measurements, and laboratory results. Patient compliance was good and adverse effects were rare, minor, and manageable with nonpharmacological means.
Volume
11
First Page
1055131
Last Page
1055131
ISSN
2296-2360
Published In/Presented At
Youssef, D. E., Handler, S. S., Richards, S. M., Sheppard, C. A., Smith, J., Tillman, K., Pietrosanu, M., Kirkpatrick, E., & Bates, A. (2023). Multicenter review of a tadalafil suspension formulation for infants and children with pulmonary hypertension: A North American experience. Frontiers in pediatrics, 11, 1055131. https://doi.org/10.3389/fped.2023.1055131
Disciplines
Medicine and Health Sciences
PubMedID
36776903
Department(s)
Fellows and Residents
Document Type
Article